Clinical Guidance
A significant proportion of Ebola infections in healthcare settings occur during PPE removal (doffing). Proper training in donning and doffing is as important as the PPE itself.
Health-Worker Infections in 2026 — WHO's Series
| WHO report (data date) | HCW confirmed cases | HCW deaths | HCW CFR | All DRC confirmed cases | HCW share |
|---|---|---|---|---|---|
| DON 612 (July 1) | 102 | 25 | 24.5% | 1,460 | 7.0% |
| DON 613 (July 15) | 119 | 36 | 30.3% | 2,124 | 5.6% |
| DON 614 (July 30) | 151 | 44 | 29% | 3,605 | 4.2% |
| DON 615 (August 9 / 12) | ≥155 | 45 | 29% | 4,665 | 3.3% |
| DON 616, 617 (Aug 26, Sept 7) | Not restated | 5,794 · 6,757 | — | ||
Two readings. First, the health-worker fatality rate (about 29–30%) has run well below the outbreak's overall crude CFR of 44–48% at the same dates — consistent with health workers being recognised and treated earlier. Second, early in the outbreak health workers were a much larger share: 16 of the first 125 confirmed DRC cases (12.8%) and at least 3 of Uganda's first 9 (Elvis Akem et al., PLOS Global Public Health 2026), and 4 of Uganda's 20 confirmed cases overall were health workers infected during the attempted resuscitation of a probable case who was embalmed before testing (CDC MMWR 2026;75(35):551). That is the classic amplification pattern — the first cases are missed, and the people who treat them are infected — and the reason CDC's guidance stresses early consideration of Ebola in any febrile patient with exposure history.
The 2014 comparison: in Sierra Leone, 199 of the first 3,854 laboratory-confirmed cases (5.2%) were health workers as of October 31, 2014, "a much higher estimated cumulative incidence" than in the general population, peaking at 65 cases in August 2014 and concentrated at Kenema General Hospital (Kilmarx et al., CDC MMWR 2014;63:1168).
🧤 PPE Requirements
Full Ebola PPE per CDC/WHO guidance includes:
- Fluid-resistant or impermeable gown
- Double gloves (inner and outer nitrile)
- N95 respirator or PAPR (powered air-purifying respirator)
- Full face shield or goggles
- Boots or shoe covers
- Head cover
- Apron for high-fluid-exposure procedures
Trained donning and doffing procedures are critical — a significant proportion of HCW infections occur during PPE removal. CDC's hospital guidance (June 24, 2026) requires adequate space for donning and doffing, a log of everyone entering the patient's room, and suggests posting personnel at the door to check PPE use; it prefers disposable filtering-facepiece respirators over reusable ones because of the risk to whoever reprocesses them.
🏥 Patient Isolation
Confirmed or suspected Ebola patients must be placed in:
- A single-patient room with a private bathroom
- Negative-pressure airborne infection isolation room (AIIR) if available
- Dedicated patient care equipment — no sharing with other patients
- Restricted access — only essential personnel enter
The CDC recommends that all healthcare facilities maintain a written Ebola response plan and designate an Ebola response team that can be activated prior to any suspected patient arrival. Aerosol-generating procedures (intubation, open suctioning, BiPAP, bronchoscopy) should be avoided where possible and otherwise done in an airborne-infection isolation room with the fewest staff present (CDC, June 24, 2026).
📋 Reporting Requirements
In the United States, Ebola is a nationally notifiable disease. Healthcare providers must:
- Report immediately to state/local health department upon suspicion
- Contact the CDC Emergency Operations Center: (770) 488-7100
- Do not wait for laboratory confirmation before reporting a suspected case
- Coordinate with your state health department for specimen transport authorization
🔬 Diagnosis & Testing
For suspected Ebola in a patient with compatible symptoms and epidemiologic risk:
- Notify your state health department immediately — do not ship specimens without authorization
- RT-PCR (reverse transcription polymerase chain reaction) is the gold-standard diagnostic
- Testing in the U.S. is coordinated through CDC's Laboratory Response Network (LRN)
- Antigen-capture ELISA and serology (antibody testing) are used for convalescent patients
- For the 2026 Bundibugyo virus outbreak: confirm assay suitability — contact CDC for current diagnostic guidance. The species matters for assays: Towner et al. reported in 2008 that Bundibugyo virus's sequence divergence had "important implications for design of future diagnostic assays," and DRC's national laboratory first detected the 2026 virus as "non-Zaire ebolavirus" before species confirmation (Elvis Akem et al., 2026)
- CDC's clinical guidance (May 27, 2026): do not delay testing for more likely diagnoses such as malaria while evaluating for Ebola — most ill returning travelers have something else
- CDC Ebola Clinical Guidance for Healthcare Providers
- WHO Ebola Infection Prevention and Control Guidance
- CDC Clinical Guidance for Ebola EVD
- CDC Emergency Operations Center: (770) 488-7100 (24/7)
What Clinical Care Actually Involved — the U.S. and European Series
The most detailed account of Ebola clinical management outside Africa is Uyeki et al.'s review of all 27 laboratory-confirmed patients treated in U.S. and European hospitals from August 2014 through December 2015 (NEJM 2016;374:636). 22 of the 27 (81%) were healthcare personnel — the occupational profile of this disease in a nutshell. Median age was 36. At onset the commonest features were fatigue (80%) and fever or feverishness (68%); the course was dominated by diarrhea and by low albumin, sodium, potassium, calcium and magnesium. Fourteen patients (52%) developed hypoxemia and nine (33%) reduced urine output, five of them anuria. Aminotransferases peaked a median of 9 days after onset; blood viral RNA peaked at a median of 7 days and cleared after a median of 17.5 days.
What was done: nearly all received IV fluids and electrolytes; 9 (33%) were mechanically ventilated; 5 (19%) received continuous renal-replacement therapy; 22 (81%) received empirical antibiotics; 23 (85%) received investigational therapies, 19 of them at least two. Five died (18.5%), three with respiratory and renal failure. The authors' conclusion is that "close monitoring and aggressive supportive care… were needed; 81.5% of these patients who received this care survived."
The 2026 Uganda series adds the first Bundibugyo laboratory profile: on admission all 18 treatment-unit patients had elevated AST, low albumin and low sodium; 72% had leukopenia and 28% thrombocytopenia (CDC MMWR 2026;75(35):551). All 18 received remdesivir under compassionate use; one had a severe rash with hepatorenal toxicity that resolved on stopping the drug. See the treatment page for what that series can and cannot show.
High-Risk Exposure Management for Staff (CDC, June 24, 2026)
CDC's definition of a high-risk exposure includes percutaneous, mucous-membrane or skin contact with a patient's blood or body fluids; direct contact with a suspected or confirmed patient; providing care without all recommended PPE or with a breach; and living in the same household as a patient. Staff with a high-risk exposure should be quarantined, monitored at least daily for fever for 21 days after the last exposure, restricted from work and from commercial transport for that period, and receive medical evaluation. Facilities are asked to make sick-leave policies "non-punitive, flexible and consistent with public health guidance" — the guidance recognises that staff who fear losing pay hide symptoms.
What Is Not Known
- The current health-worker infection count in DRC. WHO last restated it on August 14 (data to August 9); its August 28 and September 10 reports gave overall counts only.
- Whether any 2026 health-worker infection occurred despite full, correctly used PPE. WHO attributes the infections to "limited protective equipment, security concerns, and infection-control gaps"; no breach-level analysis has been published.
- The efficacy of Ervebo for health workers against Bundibugyo virus — 2,007 health and frontline workers had been vaccinated under a research protocol by September 6, 2026 precisely because it is unknown (WHO DON 617).
Compared to what? For Ebola's risk alongside 14 other viruses, see the Virus Risk Perspective and this site's Ebola risk perspective.
Frequently Asked Questions
What PPE is required for Ebola patient care?
Full Ebola PPE per CDC/WHO guidance includes: fluid-resistant or impermeable gown, double gloves (inner and outer nitrile), N95 respirator or PAPR, full face shield or goggles, boots or shoe covers, and a head cover. An apron is added for high-fluid-exposure procedures. Trained donning and doffing is critical — most HCW infections occur during PPE removal. All PPE use must be supervised by a trained observer. See complete PPE guidance →
What should I do if I suspect Ebola in a patient?
Per CDC protocol, immediately isolate the patient in a single-patient room with a private bathroom and apply full Ebola PPE before any contact. Because Ebola is a nationally notifiable disease, federal reporting requirements mandate reporting suspected cases immediately to your state or local health department — do not wait for laboratory confirmation. Call the CDC Emergency Operations Center at (770) 488-7100 (24/7). Your state health department coordinates CDC Laboratory Response Network testing authorization. Do not self-ship specimens.
Is Ebola reportable in the United States?
Yes. Ebola is a nationally notifiable disease. Report suspected cases immediately to your state or local health department upon clinical suspicion — do not wait for laboratory confirmation. The state health department coordinates with CDC for testing, patient transport to a designated Regional Ebola and Special Pathogen Treatment Center (RESPTC), and contact tracing.
Do the approved Ebola antivirals work against the 2026 Bundibugyo outbreak?
Their effectiveness is not established. Inmazeb and Ebanga are monoclonal antibodies targeting specific Zaire ebolavirus glycoprotein epitopes. The 2026 DRC outbreak is caused by Bundibugyo virus — a different species with a different glycoprotein — so cross-protection cannot be assumed. WHO technical groups are reviewing candidate therapeutics for Bundibugyo virus. Contact CDC at (770) 488-7100 for current treatment guidance.
What is the standard diagnostic test for Ebola?
RT-PCR is the gold-standard diagnostic for Ebola virus disease. In the U.S., testing runs through CDC's Laboratory Response Network (LRN) and requires state health department authorization before specimens are shipped. For the 2026 Bundibugyo virus outbreak, confirm assay suitability with CDC for specific diagnostic guidance.
Sources & References
- Centers for Disease Control and Prevention. Clinical Guidance for Ebola Disease. Page dated May 27, 2026. cdc.gov/ebola/hcp/clinical-guidance
- Centers for Disease Control and Prevention. Infection Prevention and Control Recommendations for Patients in U.S. Hospitals who are Suspected or Confirmed to have Selected Viral Hemorrhagic Fevers. Page dated June 24, 2026. cdc.gov/viral-hemorrhagic-fevers/hcp/infection-control
- World Health Organization. Disease Outbreak News 612 (July 3), 613 (July 17), 614 (August 1), 615 (August 14), 616 (August 28) and 617 (September 10, 2026): Ebola disease caused by Bundibugyo virus. who.int/…/2026-DON617
- Uyeki TM, et al. Clinical Management of Ebola Virus Disease in the United States and Europe. N Engl J Med 2016;374:636–46. doi:10.1056/NEJMoa1504874
- Mutegeki M, et al. Notes from the Field: Clinical Characteristics of Patients with Ebola Disease Caused by Bundibugyo Virus — Uganda, 2026. MMWR 2026;75(35):551–553. doi:10.15585/mmwr.mm7535a2
- Kilmarx PH, et al. Ebola virus disease in health care workers — Sierra Leone, 2014. MMWR 2014;63(49):1168–71. PMID 25503921
- Elvis Akem T, et al. Operational epidemiology of the early phase of the 2026 Bundibugyo virus disease outbreak. PLOS Glob Public Health 2026;6(8):e0006680. doi:10.1371/journal.pgph.0006680
- Towner JS, et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008;4(11):e1000212. doi:10.1371/journal.ppat.1000212
- World Health Organization. Ebola disease — fact sheet. Updated May 2026. who.int/news-room/fact-sheets/detail/ebola-disease
- World Health Organization. Infection prevention and control guidance for Ebola and Marburg disease. iris.who.int/handle/10665/130596
